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An increasing number of genetic studies suggest that the pathogenesis of Parkinson’s
disease (PD) and cancer share common genes, pathways, and mechanisms. Despite a
disruption in a wide range of similar biological processes, the end result is very different:
uncontrolled proliferation and early neurodegeneration. Thus, the links between the
molecular mechanisms that cause PD and cancer remain to be elucidated. We propose
that chronic inflammation in neurons and tumors contributes to a microenvironment that
favors the accumulation of DNA mutations and facilitates disease formation. This article
appraises the key role of microglia, establishes the genetic role of COX2 and CARD15
in PD and cancer, and discusses prevention and treatment with this new perspective in
mind. We examine the evidence that chronic inflammation is an important link between
cancer and PD.
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INTRODUCTION
The three early, typical symptoms of Parkinson’s disease (PD) are static tremors, muscle rigidity,
and bradykinesia, which result from the degeneration of dopaminergic neurons in the midbrain.
In contrast, cancer is a disease caused by the clonal proliferation of selectively advantageous
cells. Although the two may appear distinct, epidemiological studies have revealed some parallels.
Doshay (1954) found a decreased frequency of cancer incidence in patients with PD, but the
reason for this was unknown. Case-controlled and large prospective studies reported a lower rate of
smoking-related and non-smoking-related cancers in PD patients. Melanoma, thyroid, and breast
cancer were revealed to have an increased incidence in PD patients (D’Amelio et al., 2009; Liu et al.,
2011). There are a number of potential explanations for the inverse association. One of theories
between PD and skin cancer may be associated with the mode of therapy, such as Levodopa, rather
than with the disease itself (Paisan-Ruiz and Houlden, 2010). However, some observations do not
agree with the view that this may be a result of drug treatment (Fiala et al., 2003; Zanetti et al., 2006).
Moreover, it was suggested that PD patients with a low incidence of cancer may be associated with
the negative correlation between PD and smoking (Hernan et al., 2002). Although the reduced risk
of smoking-related cancers can be explained in PD patients, it cannot decipher the risk of non-
smoking-related cancers. Thus, more data are needed to confirm the epidemiological relationship
between PD and cancer.
Recently, the unusual epidemiological information between PD and cancer is increasingly
becoming of interest to many investigators. Genetic studies provide additional understanding,
since many familial PD genes have been associated with cancer, such as parkin (PARK2), PINK1
(PARK6), DJ-1 (PARK7), and LRRK2 (PARK8; Table 1). However, the same gene’s variants may
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TABLE 1 | Parkinson’s disease (PD) involved genes identified in cancer.
Gene PD locus Chromosome
location
Inheritance
in PD
Expression in cancer Proliferation
in cancerb
Cancer
α-Synuclein PARK1/PARK4 4q21–q23 AD Overexpressed (not
express in normal
tissue)
+ Brain tumors (Kawashima et al., 2000), Melanoma
(Matsuo and Kamitani, 2010), and Ovary cancer
(Bruening et al., 2000)
Parkin PARK2 6q25.2–q27 AR Decreaseda − Glioblastoma, Colon cancer, and Lung cancer (Veeriah
et al., 2010)
UCHL1 PARK5 4p14 AD Silenced (via CpG
methylation)
− Nasopharyngeal carcinoma (Li et al., 2010), Colorectal
cancer (Okochi-Takada et al., 2006)
PINK1 PARK6 1p35–p36 AR Decreaseda − Breast cancer (Berthier et al., 2011)
DJ-1 PARK7 1p36 AR Overexpressed + Non-small-cell lung cancer (MacKeigan et al., 2003)
LRRK2 PARK8 12p11.2–q13.1 AD Overexpressed + Papillary renal cell carcinoma and Thyroid cancer
(Looyenga et al., 2011)
AD, autosomal dominant; AR, autosomal recessive. aThe telomeric end of chromosome 1p is subject to frequent deletion and rearrangement in many cancers.
b± denotes proliferation and anti-proliferation.
lead to distinct effects due to the different cell backgrounds
associated with dopaminergic neurons and cancer cells.
PD-related genes participate in a wide variety of cellular
processes, including the misfolding and degradation of proteins,
mitochondrial damage, response to oxidative stress, cell cycle
control, and DNA repair (Figure 1). These processes all have
an important influence on the occurrence and development
of PD and cancer. The PI3K/AKT/mTOR pathway also plays
important roles in both cell growth and death. Some common
cellular pathways and genes have been explained in our
work (Zhiming et al., 2014). Notably, neuroinflammation is
increasingly considered a double-edged sword (Wyss-Coray
and Mucke, 2002). Acute inflammation can repair damage
and promote healing, but long-term chronic inflammation can
severely damage the body. Chronic inflammation is considered a
driving force behind many chronic diseases, certainly including
cancer and neurodegenerative disease. In this article, we further
discuss the relationship between PD and cancer from the
perspective of chronic inflammation. This will provide an
increased understanding and improved treatment approaches
for both diseases.
MICROGLIA: A KEY PLAYER
Inflammation and PD have an established link via microglia,
which are the resident immune cells of the central nervous
system (CNS). Under physiological conditions, microglia are
inactive, have a small cell body, and exhibit highly ramified
morphology. In response to injury or toxic factors, microglia
transform into activated microglia, migrate to the lesion
area, and phagocytose cellular debris or damaged neurons. It
is now well documented that activated microglial surround
the lost dopaminergic neurons in patients with PD and
PD animal models, which provides for the speculation that
microglia activation results in initiation and development of PD
(Tansey and Goldberg, 2010). A recent investigation revealed
that neurons could release α-synuclein oligomers, the main
component of Lewy bodies (LBs) in the substantia nigra pars
compacta (SNc) of the midbrain, which can bind to toll-like
receptors (TLRs) to activate microglia, mediating the nuclear
factor kappa B (NF-κB) pathway and causing the secretion of
inflammatory mediators, such as cytokines, eicosanoids, and
chemokines, altering immunological functions (Beraud and
Maguire-Zeiss, 2012). These immune factors not only directly
act on dopaminergic neurons to cause neuronal death but also
aggravate the inflammatory reaction and continue to activate
microglia. Activated microglia also generate and release a wide
range of reactive-free radicals and increasing evidence has
shown that the oxidative stress response plays a crucial role
in PD. The sustained production of free radicals and noxious
compounds, like superoxide or peroxynitrite, can interact with
biological macromolecules, leading to disruption to the redox
balance of neurons. Additionally, levels of pro-inflammatory
mediators, including tumor necrosis factor (TNF)-α, interleukin
(IL)-1β, IL-6, and eicosanoids are enhanced in peripheral blood
mononuclear cells (PBMCs) of PD patients (Bessler et al., 1999).
Recent studies have shown that inhibiting the microglia cascade
reactions could prevent the degradation of neurons (Burguillos
et al., 2011). The immunohistochemical demonstration of
reactive microglia suggests that chronic inflammation occurs in
affected brain regions in PD.
The brain is a common metastatic site for various types
of cancers, especially lung cancer, which suggests failure of
the immune defense in the brain environment. Microglia are
believed to be the most important immune cells in the CNS.
Interestingly, significant microglial activation has been observed
in the vicinity of glioma tumor cells (Roggendorf et al., 1996).
In contrast to CNS inflammation, microglia associated with
brain tumors do not seem to be active in inducing an effective
antitumor response. The exact mechanism of this microglial
inactivation remains unclear. There is evidence that some
cytokines, such as IL-10 released from activated microglia, play
important roles in local immunosuppression and progression
of glioma, particularly promoting proliferation of tumor cells
and their infiltration into surrounding normal brain tissue
(Wagner et al., 1999). Microglia also play an important role
in phagocytosing tumor cells. During the past decades, more
attention has been paid to the secretory property and chemotaxis
of microglia, but microglial phagocytosis is not well-studied.
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FIGURE 1 | Genes and biological processes shared in Parkinson’s disease (PD) and cancer. Overlapping biological processes of PD and cancer mainly
include the following: (a) misfolding and degradation of proteins, (b) mitochondrial damage and oxidative stress response, (c) chronic inflammation, (d) cell cycle
control and DNA repair, and (e) PI3K/AKT/mTOR pathway regulation. The α-synuclein polymer attributed to SNCA multiplication is the main component of Lewy
bodies (LBs). SNCA mutations alter the normal function of α-synuclein, which induces the PI3K/AKT/mTOR pathway and promotes cell proliferation. Under the
cascade of phosphorylating AKT, mTOR is activated by PINK1 and LRRK2. PARK2 and UCH-L1 mutations disrupt the degradation function of the ubiquitin
proteasome system (UPS), leading to the misfolding and aggregation of α-synuclein, cyclin E, and p53. PINK1 and DJ-1 mutations result in the overproduction of
free radicals and oxidative stress in the mitochondria, which causes neuron defects and stimulates cell proliferation. COX2 and CARD15 mutations activate the
NF-κB pathway and induce chronic inflammation, leading to a wide range of genetic mutations and abnormal cellular signaling. The different cellular backgrounds of
cancer cells and neurons (mitotic vs. post-mitotic cells) bring completely distinct reactions to external stimuli and internal changes: some undergo cell proliferation,
and others neuron death. The final result is two serious diseases: cancer and PD.
The activity of phagocytosis can be modulated by cancer
cells or the cancer environment. However, whether microglial
phagocytosis functions to contribute to cancer or cancer
defense still needs further investigation. A better understanding
of microglia function is important for the development of
immune-based treatment strategies against malignant brain
tumors.
PROVEN GENETIC RISK IMPLICATED IN
BOTH CANCER AND PD
Inflammation is known as the seventh most important sign of
cancer (Colotta et al., 2009). Sometimes, inflammatory mediators
are referred to as genetic mutagens, which disturb DNA repair
pathways and cell-cycle checkpoints, threatening the stability
of the genome and accumulating chromosomal alterations.
Inflammatory mediators in the microenvironment during
chronic inflammation not only help cancer cells proliferate
and escape from immune surveillance but also cause a large
number of random mutations (Grivennikov et al., 2010). A major
advantage of the cell cycle is careful checking and repair of
the damaged DNA, but post-mitotic neurons are particularly
vulnerable to the abnormal levels of mediators and accumulation
of mutations. Some mutations in two genes unequivocally
linked to chronic inflammation, namely COX2 and CARD15,
were identified in tissue samples from patients with PD and
cancer.
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Cyclooxygenase 2 (COX2)
It is well known that prostanoids have critical functions in
many cellular processes and pathophysiologic process, including
inflammation, arthritis, and pain. COX-1 and -2 are two key
enzymes in the synthesis of prostaglandins from of arachidonic
acid. COX1 is constitutively expressed in the majority of tissues
and is responsible for maintenance the normal physiological
functions. Inversely, COX2 expression is low in most normal
tissues, but it can be induced by various inflammatory stimuli
(Smith et al., 2000). High levels of COX2 have been detected
in many cancers, including gastric, breast, lung, esophageal,
and hepatocellular carcinomas, particularly in colon cancer
(Liu et al., 2003). Several lines of evidence suggest that non-
steroidal anti-inflammatory drugs (NSAIDs) and selective COX2
inhibitors are promising as anti-cancer drugs. Genetic studies
suggested that there is a strong causality between COX2 and
tumorigenesis. Polymorphisms in the COX2 gene could alter
enzyme expression, function, and/or the response to NSAIDs.
The COX2 V511A polymorphism was very near to the active
site of a molecular model (Fritsche et al., 2001). In African
Americans, the COX2 V511A polymorphism was reported to
confer a reduced susceptibility to colon cancer (Lin et al., 2002).
COX2 has been shown to activate the NF-κB pathway and the p38
and JNK MAPK pathways (Hunot et al., 2004). Polymorphisms
in the COX2 and other genes these pathways may account for
inter-individual differences in cancer susceptibility or response
to NSAIDs.
Cyclooxygenase 2 is inducible by growth factors, cytokines,
and pro-inflammatory molecules. COX2 expression in brain has
been associated with pro-inflammatory activities. COX2 has been
observed to increase in brain dopaminergic neurons of both PD
post-mortem specimens and in the PD mouse model induced
by 1-methyl-4-phenyl-1,2,3,6-tertrahydropyridine (MPTP). The
involvement of COX2 in PD pathogenesis was further evidenced
by the observation that MPTP neurodegeneration was alleviated
in COX2, but not in COX1, knock out mice (Minghetti, 2004).
Recently, the COX2 1195G > A polymorphism was considered
to be a protective factor in the onset of PD in the Chinese Han
population (Dai et al., 2015). However, the role of the COX2
variant on the generation of PD has rarely been studied. Previous
studies found that different polymorphisms of some known genes
related to PD may result in different diseases: PD or cancer due
to the differentiated background of neuronal and cancer cells
(Veeriah et al., 2010; Vasseur et al., 2012). Lopez de Maturana
et al. (2014) found that LRRK2 also affected the inflammatory
response in PD patients through regulating the expression of the
COX2 enzyme. By extension, researchers propose that the overlap
between PD and cancer is chronic inflammation, and COX2 may
be the key enzyme in the inflammatory response to combine
them.
Caspase Recruitment Domain Protein 15
(CARD15)
Caspase recruitment domain protein 15, also known as
nucleotide-binding oligomerization domain protein 2 (NOD2),
is a protein that is encoded by the CARD15 gene located on
human chromosome 16q12 (Hampe et al., 2001; Hugot et al.,
2001; Ogura et al., 2001). CARD15 is the receptor of muramyl
peptides (MDP), a component of bacterial peptidoglycan. The
binding of MDP and CARD15 activates NF-κB, resulting in
inflammatory reactions. It was shown that CARD15 mutations
are involved in the innate immune system and pathogen
recognition in terms of other complex polygenic diseases. In
2001, three laboratories identified genetic variants related to
Crohn’s disease (CD), an inflammatory bowel disease. About 40%
of CD patients in Western countries have at least one of the
three SNPs: R702W, G908R, and L1007fsinsC. The heterozygous
mutation of any of these SNPs increases the risk of CD by two-
to fourfold. In addition, multiple-locus heterozygous mutations
or homozygous mutations may lead to a more than 20-fold
increased CD risk. Nevertheless, it was reported that none of
these SNPs are involved in CD in Chinese (Han; Gao et al.,
2005), Korean (Croucher et al., 2003), and Japanese patients
(Yamazaki et al., 2002). Bialecka et al. (2007) showed that
three SNPs in CARD15 (R702W, G908R, and L1007fsinsC) were
significantly related to PD patients in a Polish population. Our
group identified P268S, an additional CARD15 SNP that might
be a risk factor for PD in a Chinese population (Ma et al., 2013).
Additionally, Crane et al. (2002) reported that P268S was related
to susceptibility of ankylosing spondylitis. Proell et al. (2008)
performed sequence comparisons and found that CARD15
shared a high degree of similarity with apoptotic protease
activating factor 1 (Apaf-1). They simulated the homologous
structure of CARD15 based on the structure of Apaf-1 and
found that P268S was located at the connexon (ligand-binding
position) before the first helix of the NOD. Replacing Pro with
Ser changed the conformation of the connexon and affected
its binding to the substrate. These experimental observations
show a possible linkage between the dysfunction of CARD15 and
neurodegenerative disease.
Whether CD-related CARD15 variants result in a loss or
gain of effect of the CARD15 receptor is still unclear, and the
mechanisms by which this alteration, in function, may enhance
the susceptibility to CD need to be clarified. Patients with CD
have an enhanced risk of developing colorectal cancer (Gasche
and Carethers, 2004; D’Amelio et al., 2009). CARD15 mutations
may also increase the susceptibility to colorectal cancer in non-
CD Caucasians (Papaconstantinou et al., 2005; Roberts et al.,
2006). These investigations demonstrated that immune system
mechanisms are involved in the etiology of cell damage in CD
and provided evidence for an ongoing active pathological process.
Inflammation can be triggered by invading microbes and also
internally within the organism by diseases that affect the nervous
system. There are three common outcomes of inflammation.
First, the offending agent or process is inactivated, and the
injury is repaired. Second, the host loses the battle and dies or
suffers irreparable tissue damage. Finally, neither the organism
nor the injurious process prevails, resulting in a prolonged battle
that provides a fertile ground for the development of chronic
inflammatory conditions. This last outcome may be closely
related to neurodegenerative diseases and cancer, two of the
greatest public health problems of this century (Wyss-Coray and
Mucke, 2002).
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THERAPEUTIC INTERVENTIONS
INSPIRED BY THEIR LINKS
Lower rates of cancer mortality and incidence in patients with
PD have given rise to speculation about risks or preventative
factors common to both diseases. Thus, unraveling the link
between PD and cancer may open a new therapeutic window
for both diseases. Epidemiological investigations revealed that
taking NSAIDs can help lower your risk of PD development,
and patients with colorectal cancer treated with NSAIDs
showed 40–50% decreased mortality compared with those
not using these drugs (Subbaramaiah and Dannenberg, 2003).
The important role of mitotic activation in neurodegeneration
raises the possibility of the cell cycle as a therapeutic
target. Drugs, such as retinoic acid, simvastatin, and IL-
1, which lead to cell cycle arrest at the G0/G1 interface,
might prevent neurons from committing themselves to mitosis
and therefore apoptosis. Another intervention would be to
interfere with cellular signaling cascades that drive cell cycle
progression or apoptosis, like Mithramycin (Sleiman et al.,
2011). A number of other compounds have anti-neoplastic
and neuroprotective properties, including inhibitors of histone
deacetylase (Sleiman et al., 2009), mTOR (mammalian target
of rapamycin), and transglutaminase (Ravikumar et al., 2004).
Along with the cell cycle, the ubiquitin proteasome system
is a common link between cancer and neurodegeneration,
and an exciting target for new therapies. Because defective
proteolysis is common to all neurodegenerative diseases, the
potential clinical effect of a proteasome activator is beneficial
and should be a focus of drug development. Trials of
proteasome activators in PD should be carefully designed to
capture any result of a related increased risk for malignancy
because upregulation of the proteasome is associated with many
cancers.
In 2010, Datamonitor Inc., (USA) estimated that there
were over 1.5 million PD patients in the United States,
Japan, France, Germany, Italy, Spain, and UK combined, one
third of which are in the United States. Combined with the
aggravated aging problem, the incidence of PD is increasing
annually (Huynh, 2011). Medication is usually the first treatment
option for PD. Levodopa is currently the most effective
medication, but long-term use can reduce its effectiveness and
cause complications such as motor dysfunction. Most brain
degenerative diseases are incurable, and it is difficult to obtain
the brain tissues from the patients with significant impairment.
However, large amounts of cancer-related studies have been
carried out over the past 30 decades, and many small molecule
agents have been demonstrated as cancer therapeutic drugs
or are now being assessed in clinical trials. Therefore, the
extensive therapeutic developments in cancer studies may help
the identification of diagnostic and prognostic markers for
neurodegeneration that could contribute to improve treatments
for PD.
CONCLUSION
Both cancer and PD are considered to be the consequence of
the interaction of genes and environmental factors. The key
difference is that different reactions occur in the different cellular
backgrounds of cell division and cell death. The inflammation
hypothesis is one explanation for comparisons between PD
and cancer. The immune factors and free radicals released
from chronic inflammatory reactions not only promote disease
occurrence but also allow cellular DNA to accumulate mutations
more easily, forming proteins with aberrant functions. The
abundant therapeutic achievements in cancer studies will allow
researchers to identify diagnostic markers and treatments for
neurodegenerative disease and vice versa.
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